SMS Pharma.

When is the next results date for SMS Pharma.?

No Upcoming Board Meetings

Who are in the management team of SMS Pharma.?

As of March 2022, the management team of SMS Pharma includes P Ramesh Babu (Chairman & Managing Director), P Sarath Kumar, Thummala Neelaveni, Shravan Kudaravalli, Sarvepalli Srinivas (all Independent Directors), Vamsi Krishna Potluri (Executive Director), and Thirumalesh Tumma (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2022, the management team of SMS Pharma includes the following individuals:<BR><BR>1. P Ramesh Babu - Chairman & Managing Director<BR>2. P Sarath Kumar - Independent Director<BR>3. Thummala Neelaveni - Independent Director<BR>4. Shravan Kudaravalli - Independent Director<BR>5. Sarvepalli Srinivas - Independent Director<BR>6. Vamsi Krishna Potluri - Executive Director<BR>7. Thirumalesh Tumma - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does SMS Pharma. do?

SMS Pharmaceuticals Ltd manufactures Active Pharma Ingredients and intermediates in the pharmaceuticals industry. As of March 2025, it reported net sales of ₹248 Cr and a net profit of ₹20 Cr, with a market cap of ₹2,205 Cr.

Overview:<BR>SMS Pharmaceuticals Ltd is engaged in the manufacturing of Active Pharma Ingredients and their intermediates within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated in December 1987, SMS Pharmaceuticals Ltd has maintained its focus on the production of bulk drugs. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 248 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 20 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 2,205 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 32.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.15% <BR>Debt-Equity: 0.42 <BR>Return on Equity: 10.81% <BR>Price to Book: 3.45 <BR><BR>Contact Details:<BR>Address: 19 III Rd 71 Opp Bharatividya, Bhavan Public Sch Jubilee Hill Hyderabad Telangana : 500096 <BR>Tel: 91-40-66288888 <BR>Email: info@smspharma.com <BR>Website: http://www.smspharma.com

Has SMS Pharma. declared dividend?

SMS Pharmaceuticals Ltd has declared a 40% dividend, amounting to ₹0.40 per share, with an ex-date of September 23, 2024. The company has shown strong long-term performance, with total returns of 477.41% over the past 5 years.

SMS Pharmaceuticals Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: ₹0.40<BR>- Ex-date: 23 Sep 2024<BR><BR>Dividend Yield: 0.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.34%, with a dividend return of 0%, resulting in a total return of -2.34%.<BR><BR>Over the past year, the price return was 27.02%, the dividend return was 0.19%, leading to a total return of 27.21%.<BR><BR>In the last 2 years, the price return was 170.68%, with a dividend return of 0.76%, culminating in a total return of 171.44%.<BR><BR>For the 3-year period, the price return was 204.5%, the dividend return was 1.34%, resulting in a total return of 205.84%.<BR><BR>In the last 4 years, the price return was 55.42%, with a dividend return of 0.75%, leading to a total return of 56.17%.<BR><BR>Over the past 5 years, the price return was 475.4%, with a dividend return of 2.01%, resulting in a total return of 477.41%.<BR><BR>Overall, SMS Pharmaceuticals Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the longer term, despite some fluctuations in the shorter periods.

Who are the peers of the SMS Pharma.?

SMS Pharma's peers include Senores Pharma, IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, Amrutanjan Health, Windlas Biotech, Syncom Formulations, and Anuh Pharma. In terms of performance, SMS Pharma has an average management risk, below average growth, and a 1-year return of -0.79%, better than Novartis India but worse than its other peers.

Peers: The peers of SMS Pharma. are Senores Pharma., IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, Amrutanjan Healt, Windlas Biotech, Syncom Formul., and Anuh Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, while Average management risk is found at IOL Chemicals, Novartis India, Windlas Biotech, Syncom Formul., Anuh Pharma, and SMS Pharma. Below Average management risk is noted at Senores Pharma., Panacea Biotec, and Solara Active. For growth, Excellent growth is seen at Senores Pharma., while Good growth is found at Novartis India, Average growth at Anuh Pharma, and Below Average growth at IOL Chemicals, Panacea Biotec, Solara Active, SMS Pharma., Amrutanjan Healt, Windlas Biotech, and Syncom Formul. In terms of capital structure, Excellent capital structure is noted at IOL Chemicals, Novartis India, Amrutanjan Healt, Windlas Biotech, Syncom Formul., and Anuh Pharma, while Good capital structure is found at SMS Pharma., and Below Average capital structure is observed at Senores Pharma., Panacea Biotec, and Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while the lowest is Novartis India at -9.48%. SMS Pharma.'s 1-year return is -0.79%, which is better than Novartis India but worse than all other peers. Additionally, Windlas Biotech and Anuh Pharma have negative six-month returns.

Who are the top shareholders of the SMS Pharma.?

The top shareholders of SMS Pharma include the promoters, led by Ramesh Babu Potluri, and individual investors who hold 26.35% of the shares. Institutional investors, including mutual funds and foreign institutional investors, hold a combined total of 2.51%.

The top shareholders of SMS Pharma primarily include the promoters, who hold the majority of the shares. Notably, Ramesh Babu Potluri is the promoter with the highest holding, although his specific percentage is not detailed. <BR><BR>In terms of institutional investors, mutual funds hold a total of 2.43% through three different schemes, with Quant Mutual Fund - Quant Small Cap Fund being the highest public shareholder at 2.43%. Additionally, foreign institutional investors (FIIs) hold a minor stake of 0.08%. Individual investors collectively hold 26.35% of the company's shares. <BR><BR>Overall, the promoter group and individual investors are the key stakeholders in SMS Pharma.

How big is SMS Pharma.?

As of 24th July, SMS Pharmaceuticals Ltd has a market capitalization of 2,151.00 Cr, with recent net sales of 782.75 Cr and a net profit of 69.14 Cr. Shareholder's funds are 536.33 Cr, and total assets amount to 1,034.09 Cr.

As of 24th July, SMS Pharmaceuticals Ltd has a market capitalization of 2,151.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 782.75 Cr and a Net Profit of 69.14 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 536.33 Cr and Total Assets of 1,034.09 Cr.

How has been the historical performance of SMS Pharma.?

SMS Pharma has shown consistent growth in net sales and profitability, with net sales increasing from 411.95 Cr in Mar'20 to 782.75 Cr in Mar'25, and profit after tax rising significantly to 67.40 Cr in Mar'25. Despite rising raw material costs and fluctuating cash flows, the company has improved operational efficiency and overall financial performance.

Answer:<BR>The historical performance of SMS Pharma shows a positive trend in net sales and profitability over the recent years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>SMS Pharma's net sales have increased from 411.95 Cr in Mar'20 to 782.75 Cr in Mar'25, reflecting a consistent growth trajectory. Total operating income followed a similar pattern, rising from 464.91 Cr in Mar'19 to 782.75 Cr in Mar'25. However, the raw material costs also escalated, reaching 501.87 Cr in Mar'25, up from 259.50 Cr in Mar'20. Despite this increase in costs, the operating profit (PBDIT) rose to 145.22 Cr in Mar'25 from 93.49 Cr in Mar'19, indicating improved operational efficiency. Profit before tax saw a notable increase to 92.34 Cr in Mar'25, compared to 5.35 Cr in Mar'23, while profit after tax also improved significantly to 67.40 Cr in Mar'25 from just 3.88 Cr in Mar'23. The company's total assets grew from 607.91 Cr in Mar'20 to 1,152.68 Cr in Mar'25, alongside a rise in total liabilities from 607.91 Cr to 1,152.68 Cr over the same period. Cash flow from operating activities improved to 81.00 Cr in Mar'25, up from 22.00 Cr in Mar'23, although cash flow from investing activities showed a negative trend, reaching -123.00 Cr in Mar'25. Overall, SMS Pharma's financial performance indicates a robust growth in sales and profitability, despite rising costs and fluctuating cash flows.

Is SMS Pharma. technically bullish or bearish?

As of November 26, 2025, the trend is bullish with strong indicators like MACD and Bollinger Bands supporting this, although caution is advised due to a mildly bearish KST and Dow Theory signals.

As of 26 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this position. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. The daily moving averages are bullish, reinforcing the positive momentum. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bearish stance on the weekly, which suggests some caution. Overall, the strength of the bullish trend is supported by the strong performance in the last week, with a return of 13.99% compared to the Sensex's 0.50%.

Is SMS Pharma. overvalued or undervalued?

As of November 26, 2025, SMS Pharma is considered overvalued with a PE ratio of 35.81, an EV to EBIT ratio of 26.04, and a Price to Book Value of 4.14, all indicating a premium compared to peers, despite a strong year-to-date return of 34.50%.

As of 26 November 2025, the valuation grade for SMS Pharma has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 35.81, an EV to EBIT ratio of 26.04, and a Price to Book Value of 4.14, all of which suggest a premium valuation compared to peers.<BR><BR>In comparison to its industry peers, SMS Pharma's PE ratio is higher than Sun Pharma's 37.53 and significantly above Cipla's more attractive 22.59. The PEG ratio of SMS Pharma stands at 1.26, which is on the higher side when compared to the industry average, further reinforcing the overvaluation stance. Notably, SMS Pharma has outperformed the Sensex with a year-to-date return of 34.50% compared to the Sensex's 9.56%, but this strong performance does not mitigate the concerns regarding its current valuation.

Are SMS Pharmaceuticals Ltd latest results good or bad?

SMS Pharmaceuticals Ltd's latest results show strong year-on-year growth with a net profit increase of 28.67% and net sales up 21.40%. However, there are concerns due to sequential declines in both profit and sales, indicating potential volatility in performance.

The latest results for SMS Pharmaceuticals Ltd present a mixed picture. On one hand, the company achieved a consolidated net profit of ₹23.47 crore for Q3 FY26, which reflects a strong year-on-year growth of 28.67%. Additionally, net sales increased by 21.40% year-on-year to ₹210.45 crore, indicating robust demand for its products.<BR><BR>However, there are notable concerns regarding sequential performance. Both net profit and net sales experienced declines of 7.27% and 13.19% respectively compared to the previous quarter. This volatility is not uncommon in the API business, which can be influenced by customer ordering patterns and product mix variations.<BR><BR>Despite these fluctuations, SMS Pharmaceuticals showed commendable margin resilience, with an operating margin of 20.74%, up from 19.16% year-on-year. The PAT margin also improved to 11.02%, reflecting effective cost management.<BR><BR>Overall, while the year-on-year growth figures are positive and suggest operational improvements, the sequential declines raise questions about the sustainability of this growth. Investors may need to weigh these factors carefully when assessing the company's performance.

Should I buy, sell or hold SMS Pharmaceuticals Ltd?

Why is SMS Pharmaceuticals Ltd falling/rising?

As of 05-May, SMS Pharmaceuticals Ltd's stock price is Rs 402.10, down 0.8%, but it has increased 29.65% year-to-date and 64.06% over the past year. Despite today's decline and reduced investor interest, strong financial results suggest the stock may be a hold.

As of 05-May, SMS Pharmaceuticals Ltd's stock price is currently at Rs 402.10, reflecting a decrease of Rs 3.25 or 0.8%. Despite this decline, the stock has shown strong performance over longer periods, with a year-to-date increase of 29.65% and a remarkable 64.06% rise over the past year, significantly outperforming the Sensex, which has decreased by 9.63% in the same timeframe.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.21%. Although it reached an intraday high of Rs 413.45, the overall trading activity suggests a decline in investor participation, with delivery volume falling by 22.06% compared to the five-day average. This reduced interest may contribute to the current price drop.<BR><BR>However, the company has reported positive financial results, with a 50.83% growth in profit after tax and a 22.37% increase in net sales over the latest six months. Additionally, the stock has consistently generated returns over the last three years, outperforming the BSE500 in each of the last three annual periods. Despite the current price decline, these factors indicate a solid underlying performance, suggesting that the stock may be viewed as a hold rather than a sell.

Which are the latest news on SMS Pharma.?